Transforming Lives Through Precision Therapies

About Us

We are a clinical-stage biotechnology company dedicated to developing a portfolio of precision therapies targeting a wide range of molecularly defined diseases. Our lead clinical program is a next-generation, highly CNS penetrant tropomyosin receptor kinase (TRK) inhibitor, for patients with NTRK fusion-driven cancers.